# BioVersys AG

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bioversys-ag
Canonical HTML page: https://getbiobrief.com/entity/bioversys-ag

## Timeline

- **2026-03-18**: 2025 Earnings Release — BioVersys officially reports 2025 financial results and corporate highlights.
- **2026-03-12**: AlpE Phase 2b Milestone — First patient dosed in the Phase 2b clinical trial of AlpE for pulmonary tuberculosis.
- **2026-03-05**: Reporting Announcement — Company announces date for full-year 2025 results and business update.
- **2025-12-31**: Fiscal Year End — BioVersys concludes its 2025 fiscal year with key pipeline advancements.

## Recent coverage (1 stories)

### BioVersys Advances AMR Pipeline with Phase 2b Milestone and 2025 Results
2026-03-18 08:04:09 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

BioVersys AG reported its full-year 2025 financial results, highlighting the successful transition of its lead candidate AlpE into Phase 2b clinical trials for pulmonary tuberculosis. The company's progress underscores its leadership in the antimicrobial resistance (AMR) space as it moves toward late-stage clinical validation.
Full story: https://getbiobrief.com/story/bioversys-2025-results-amr-pipeline-milestones

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.